Bone Marrow Cancer
Comprehensive treatment for bone marrow cancers including multiple myeloma, myelodysplastic syndromes, and other bone marrow malignancies with chemotherapy, targeted therapy, and stem cell transplantation.
Bone Marrow Cancer
Hematologic Malignancies
Overview
Comprehensive treatment for bone marrow cancers including multiple myeloma, myelodysplastic syndromes, and other bone marrow malignancies with chemotherapy, targeted therapy, and stem cell transplantation.
When to Consult
Upon diagnosis of bone marrow cancer, abnormal blood counts, or bone marrow biopsy findings.
What to Bring
Complete blood count (CBC), bone marrow biopsy reports, flow cytometry, cytogenetic studies, and imaging scans.
Risk Factors
Causes
Treatment Options
Chemotherapy
Systemic drug therapy tailored to specific bone marrow cancer type (multiple myeloma, myelodysplastic syndromes, etc.). Multi-drug regimens including alkylating agents, anthracyclines, and other cytotoxic medications based on cancer subtype.
Stem Cell Transplantation
Autologous (patient's own) or allogeneic (donor) stem cell transplant to replace diseased bone marrow. High-dose chemotherapy followed by stem cell infusion offers potential cure for selected patients with bone marrow cancers.
Targeted Therapy
Precision treatments including proteasome inhibitors (bortezomib, carfilzomib) for multiple myeloma, hypomethylating agents (azacitidine, decitabine) for MDS, and other targeted agents based on molecular profiling.
Immunotherapy
Immune checkpoint inhibitors, monoclonal antibodies (daratumumab, elotuzumab for multiple myeloma), and CAR-T cell therapy for relapsed/refractory disease. Helps immune system recognize and attack cancer cells.
Supportive Care
Blood transfusions, growth factors (erythropoietin, G-CSF), antibiotics for infection prevention, and bone-strengthening medications (bisphosphonates). Essential for managing complications and maintaining quality of life.
Watchful Waiting
Active monitoring without immediate treatment for early-stage, asymptomatic bone marrow cancers (especially indolent multiple myeloma or low-risk MDS). Treatment initiated when symptoms develop or disease progresses.